Evidence map›Paper›PMID 39812332›Full record

ArticleBioanalysis2025

Development and validation of an ultrasensitive qPCR method to identify and quantify EGFR T790M in cell-free DNA.

Shenglei Yuan, Nan Jia, Guofu Lu, Jinping Lai, Wenzhong Liang, Lan Li, Chenpu Zhang, Jianbo Diao

Abstract readValidation Study
PubMed Full text at PMC Publisher
In one paragraph

Article in Bioanalysis, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Shenglei YuanBioanalytical Services Department, WuXi AppTec (Shanghai) Co. Ltd, Shanghai, China.ORCID 0009-0009-9618-2200
Nan JiaBioanalytical Services Department, WuXi AppTec (Shanghai) Co. Ltd, Shanghai, China.ORCID 0000-0002-6317-269X
Guofu LuBioanalytical Services Department, WuXi AppTec (Shanghai) Co. Ltd, Shanghai, China.
Jinping LaiBioanalytical Services Department, WuXi AppTec, Plainsboro, NJ, USA.
Wenzhong LiangBioanalytical Services Department, WuXi AppTec (Shanghai) Co. Ltd, Shanghai, China.
Lan LiBioanalytical Services Department, WuXi AppTec (Shanghai) Co. Ltd, Shanghai, China.
Chenpu ZhangBioanalytical Services Department, WuXi AppTec (Shanghai) Co. Ltd, Shanghai, China.
Jianbo DiaoBioanalytical Services Department, WuXi AppTec (Shanghai) Co. Ltd, Shanghai, China.ORCID 0009-0009-3191-7616

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundCirculating tumor DNA (ctDNA) is a promising biomarker for cancer prognosis and drug development. A major challenge in the ctDNA determination method is discriminating ctDNA from highly similar but significantly more abundant wild-type DNA sensitively and accurately.

methodAn ultrasensitive qPCR method termed Triple Enrichment Amplification of Mutation PCR (TEAM-PCR) was developed to detect EGFR T790M mutation.

resultsEGFR T790M was quantified over the assay range of 25-10

conclusionThis study established and validated a qPCR-based strategy to detect EGFR T790M mutation with ultra-high sensitivity and reliability.

Indexed as

Cell-Free Nucleic AcidsCirculating Tumor DNAErbB ReceptorsReal-Time Polymerase Chain ReactionHumansLimit of DetectionMutationReproducibility of ResultsCell-Free Nucleic AcidsCirculating Tumor DNAEGFR protein, humanErbB ReceptorsbioanalysisctDNAEGFR T790MLODmethod validationNSCLCpoint mutationqPCRsensitivityTEAM-PCR

Identifiers

PMID39812332
PMCPMC11749345

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.